Actelion Must Pay Asahi $550M In Fasudil Suit: Jury

Law360, New York (April 29, 2011, 8:47 PM EDT) -- Actelion Ltd. on Friday was ordered by a California state court jury to pay Asahi Kasei Pharma Corp. $550 million in damages for interrupting an Asahi licensing agreement to develop hypertension drug Fasudil after acquiring CoTherix Inc. in 2007.

The jury in California Superior Court found that Actelion and CoTherix had acted with malice in interfering with Asahi's 2006 agreement with CoTherix to develop and commercialize Fasudil. The deal soured in 2007 when CoTherix pulled out after it was acquired by Actelion for $420 million....
To view the full article, register now.